IP
TAK icon

Ignite Planners’s Takeda Pharmaceutical TAK Stock Holding History

Ignite Planners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,634
Closed -$254K – 181
2022
Q1 		$254K Hold
17,634
– – 0.17% 159
2021
Q4 		$257K Buy
+17,634
New +$247K 0.17% 147

Other funds holding TAK

MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ignite Planners's TAK Position: Q2 2022 in Review

Ignite Planners sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 17,634 shares — an estimated $254K sold.

Ignite Planners first reported a position in TAK in Q4 2021 and held it in 2 quarters. The position peaked at $257K in Q4 2021. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

  • Ignite Planners reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Ignite Planners sold 17,634 Takeda Pharmaceutical shares in Q2 2022, an estimated $254K.
  • Ignite Planners first reported a position in Takeda Pharmaceutical in Q4 2021 and held it in 2 quarters.
  • Ignite Planners's Takeda Pharmaceutical position peaked at $257K in Q4 2021.
  • 283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Ignite Planners's 13F filing for Q2 2022, filed 15 Jul 2022.